Nuclidium

Executive Summary

Nuclidium AG is a clinical-stage biotechnology company headquartered in Basel, Switzerland, pioneering the development of next-generation copper-based radiopharmaceuticals for cancer. The company's platform leverages two copper isotopes—Copper-61 for diagnostic imaging and Copper-67 for targeted therapy—to create a theranostic pair that enables precise, personalized cancer care. By integrating diagnostics and therapeutics into a single molecular platform, Nuclidium aims to improve patient outcomes through real-time disease monitoring and tailored treatment. The company's lead candidates are currently advancing through Phase 1 clinical development, focusing on solid tumors with high unmet medical need. With a scalable manufacturing process and a clear regulatory pathway, Nuclidium is positioned to address key limitations in current radiopharmaceutical approaches, including isotope availability and target specificity. Nuclidium's strategy centers on demonstrating clinical proof-of-concept for its copper-based theranostics, potentially offering advantages over traditional beta-emitting agents through improved imaging resolution and reduced off-target toxicity. The company's early-stage data suggest favorable biodistribution and tumor uptake profiles. As it moves through Phase 1, key milestones will include safety, tolerability, and preliminary efficacy readouts. With a strong intellectual property portfolio and a focus on precision oncology, Nuclidium represents an emerging player in the expanding radiopharmaceutical landscape, targeting a market increasingly driven by theranostic approaches.

Upcoming Catalysts (preview)

• Q3 2026First Patient Dosed in Phase 1 Trial of Lead Copper-67 Therapeutic Candidate80% success
• Q4 2026Initial Phase 1 Safety and Biodistribution Data Readout60% success
• TBDAnnouncement of Strategic Collaboration for Diagnostic Imaging (Copper-61)50% success